Online inquiry

IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14062MR)

This product GTTS-WQ14062MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Paroxysmal nocturnal hemoglobinuria (PNH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14062MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8602MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ10258MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ14232MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ13205MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ8341MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ7138MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ9749MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ11910MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW